Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)

Inclusion criteria: * Male vaccinated with at least one dose of GARDASIL™ after the October 2009 FDA date of first licensure of GARDASIL™ for males Exclusion criteria all cohorts: * Female * Male vaccinated prior to the October 2009 FDA date of first licensure of GARDASIL™ for males * Male who received all doses of GARDASIL™ outside of the health plan Exclusion criteria, Regimen Completers cohort: * Male \< 9 and \> 26 years of age at first dose * Male not part of health plan at each dose * 3-dose vaccination regimen given over a period \> 12 months * Less than 28-day interval between first and second dose * Less than 12 weeks between the second and third dose * Less than 24 weeks between first and third dose Exclusion criteria, Autoimmune cohort: \- Male with less than 12 months of health plan membership prior to first dose of GARDASIL™